Generic Drug Shortages Threaten Industry’s Reputation, Hamburg Cautions
“We do have to acknowledge some important, though sometimes difficult truths,” the FDA Commissioner tells GPhA annual meeting. While noting that shortages are problems for both brand and generic firms alike, she tells ANDA manufacturers that “perceptions are not always fair, but they still matter.”
You may also be interested in...
‘In some ways our practices have played into the problems we’ve been having,’ CDER director tells GPhA annual meeting as she outlines her plan to ‘radically change’ manufacturing oversight.
During speech to the group’s annual meeting, GPhA President Ralph Neas says he is disappointed that Amgen, which is among the firms attending the gathering, is pushing biosimilar substitution restrictions in state legislatures.
OGD Director Geba says generic manufacturers still suffer from extensive quality problems, but GPhA officials argue the industry is doing fine and communications with the agency need to be more uniform.